Lipid nanoparticle vaccine adjuvants and antigen delivery systems

Patent metadata

Field	Value
Publication number	US-11406706-B2
Application number	US-202017031229-A
Country	US
Kind code	B2
Filing date	Sep 24, 2020
Priority date	Feb 25, 2014
Publication date	Aug 9, 2022
Grant date	Aug 9, 2022

Abstract

The instant invention provides for novel lipid nanoparticle (LNP) formulations, containing cationic lipids, for use as vaccine adjuvants and/or as antigen delivery systems. It is an object of the instant invention to provide LNP formulations that demonstrate enhancements in humoral and/or cellular immunogenicity of vaccine antigens, particularly subunit vaccine antigens, when utilized alone or in combination with immunostimulatory agents (e.g. small molecule or oligonucleotide TLR agonists). The instant invention further identifies physical and chemical properties of the LNP formulations that can be manipulated to enhance antigen efficiency and adjuvant tolerability in vivo.

First claim

What is claimed is:

1. A composition comprising:
a) a lipid nanoparticles (“LNP”) adjuvant comprising (13Z,16Z)-N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine, wherein the LNP adjuvant comprises 34-59 mole % (13Z,16Z)-N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine, 30-48 mole % cholesterol, 10-24% DSPC and 1-2 mole % PEG-DMG; and
b) one or more antigens;

wherein the composition provides an increased CD4+T-cell response to the one or more antigens compared to a CD4+T-cell response to the one or more antigens provided by the composition in the absence of the LNP adjuvant.

2. The composition of claim 1 , further comprising one or more agonists selected from Toll-like receptors (TLR) agonists and Stimulator of Interferon Gene (STING) agonists.

3. The composition of claim 1 , further comprising an immunostimulatory agent selected from saponin, squalene, aluminum phosphate and aluminum hydroxide.

4. The composition of claim 1 , wherein the composition is in the form of an aerosol, dispersion, solution, or suspension.

5. A method of immunizing a subject comprising administering to the subject an effective amount of the composition of claim 1 .

6. A composition comprising:
a) a lipid nanoparticles (“LNP”) adjuvant comprising (13Z,16Z)-N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine, wherein the LNP adjuvant comprises 34-59 mole % (13Z,16Z)-N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine, 30-48 mole % cholesterol, 10-24% DSPC and 1-2 mole % PEG-DMG; and
b) one or more antigens;

wherein the composition provides an enhanced antibody response to the one or more antigens compared to an antibody response to the one or more antigens provided by the composition in the absence of the LNP adjuvant.

7. The composition of claim 6 , further comprising one or more agonists selected from Toll-like receptors (TLR) agonists and Stimulator of Interferon Gene (STING) agonists.

8. The composition of claim 6 , further comprising an immunostimulatory agent selected from saponin, squalene, aluminum phosphate and aluminum hydroxide.

9. The composition of claim 6 , wherein the composition is in the form of an aerosol, dispersion, solution, or suspension.

10. A method of immunizing a subject comprising administering to the subject an effective amount of the composition of claim 6 .

11. A method of enhancing an immune response in a subject comprising administering to the subject an effective amount of a composition comprising:
a) a lipid nanoparticle (“LNP”) adjuvant comprising 34-59 mole % (13Z, 16Z)-N,N-dimethyl-3-nonyldocosa-13, 16-dien-1-amine, 30-48 mole % cholesterol, 10-24 mole % distearoylphosphatidylcholine (DSPC) and 1-2 mole % polyethylene glycol-dimyristoylglycerol (PEG-DMG); and
b) one or more antigens;

wherein the composition provides an increased γ-interferon response the one or more antigens compared to a γ-interferon response to the one or more antigens provided by the composition in the absence of the LNP adjuvant.

12. A method of enhancing an immune response in a subject comprising administering to the subject an effective amount of a composition comprising:
a) a lipid nanoparticle (“LNP”) adjuvant comprising 34-59 mole % (13Z, 16Z)-N,N-dimethyl-3-nonyldocosa-13, 16-dien-1-amine, 30-48 mole % cholesterol, 10-24 mole % distearoylphosphatidylcholine (DSPC) and 1-2 mole % polyethylene glycol-dimyristoylglycerol (PEG-DMG); and
b) one or more antigens;

wherein the composition provides an increased amount of antibody titers to the one or more antigens compared to an amount of antibody titers to the one or more antigens provided by the composition in the absence of the LNP adjuvant.

13. A method of enhancing an immune response in a subject comprising administering to the subject an effective amount of a composition comprising:
a) a lipid nanoparticle (“LNP”) adjuvant comprising 34-59 mole % (13Z, 16Z)-N,N-dimethyl-3-nonyldocosa-13, 16-dien-1-amine, 30-48 mole % cholesterol, 10-24 mole % distearoylphosphatidylcholine (DSPC) and 1-2 mole % polyethylene glycol-dimyristoylglycerol (PEG-DMG); and
b) one or more antigens;

wherein the composition provides an enhanced antibody response to the one or more antigens compared to an antibody response to the one or more antigens provided by the composition in the absence of the LNP adjuvant.

14. The method of claim 13 , wherein the composition further comprises an immunostimulatory agent selected from the group consisting of: saponin, squalene, aluminum phosphate and aluminum hydroxide.

15. The method of claim 13 , wherein the composition further comprises one or more agonists selected from the group consisting of: Toll-like receptors (TLR) agonists and Stimulator of Interferon Gene (STING) agonists.

16. The method of claim 13 , wherein the composition further provides an increased amount of antibody titers to the one or more antigens compared to an amount of antibody titers to the one or more antigens provided by the composition in the absence of the LNP adjuvant.

17. The method of claim 13 , wherein the composition further provides an increased y-interferon response the one or more antigens compared to a y-interferon response to the one or more antigens provided by the composition in the absence of the LNP adjuvant.

18. The method of claim 13 , wherein the composition further provides an increased B-cell response to the one or more antigens compared to a B-cell response to the one or more antigens provided by the composition in the absence of the LNP adjuvant.

Assignees

• Merck Sharp & Dohme
• Merck Sharp & Dohme Llc

Inventors

• Gindy Marian
• Casimiro Danilo R
• Bett Andrew
• Ter Meulen Jan H

Classifications

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• D06F81/04

  with means for adjusting height · CPC title

• A61K31/80

  Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795 · CPC title

• C12N2770/24134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• A61K2039/55577

  Saponins; Quil A; QS21; ISCOMS · CPC title